Table 1. Summary of PIK3CA mutational status and their clinicopathological features in BC samples.

Tumor #	Age	Grade	ER	PR	HER2	Epithelium mutation Nucleotide: codon (exon)
1	36	II	+	-	1+	WT
2	48	II	-	-	3+	WT
3	72	III	-	-	1+	WT
4	32	II	+	+	1+	c.3140A > G: p.His1047Arg (20)
5	44	II	+	-	1+	WT
6	34	III	-	-	3+	WT
7	62	III	+	+	3+	WT
8	67	III	-	-	3+	WT
9	47	III	+	+	1+	c.3145C > G: p.Gly1049Arg (20)
10	68	III	+	+	1+	WT
11	40	III	+	-	3+	WT
12	32	III	-	-	3+	WT
13	57	II	+	+	1+	WT
14	31	III	-	-	1+	WT
15	34	II	-	-	1+	WT
16	27	II	+	+	3+	c.3140A > G: p.His1047Arg (20)
17	42	II	-	-	1+	WT
18	54	III	+	-	1+	WT
19	66	III	+	+	3+	WT
20	55	III	+	+	3+	c.3075C > T: SNP (20)
21	61	II	+	+	1+	WT
22	50	II	+	+	1+	WT
23	40	I	+	-	1+	c.3140A > G: p.His1047Arg (20)
24	60	II	+	+	1+	c.3140A > G: p.His1047Arg (20)
25	57	III	+	+	1+	WT
26	42	III	-	-	3+	c.3075C > T: SNP (20) c.3140A > G: p.His1047Arg (20)
27	42	III	-	-	3+	WT
28	54	III	+	-	1+	c.3140A > G: p.His1047Arg (20)
29	38	III	-	-	3+	WT
30	32	II	+	-	1+	WT
31	51	II	+	+	3+	c.3073A > G: p.Thr1025Ala (20)
32	56	III	+	+	3+	c.3075C > T: SNP (20)
33	58	II	+	+	1+	c.3140A > G: p.His1047Arg (20)
34	61	II	+	+	1+	WT
35	45	I	+	+	1+	c.3075C > T: SNP (20)
36	40	II	-	-	1+	WT
37	39	III	-	-	3+	WT
38	36	II	+	+	3+	WT
39	55	III	-	-	1+	WT
40	51	II	+	-	3+	c.3140A > G: p.His1047Arg (20)
41	40	III	-	-	3+	c.3140A > G: p.His1047Arg (20)
42	41	III	+	+	1+	WT
43	46	III	-	-	1+	WT
44	50	II	+	+	1+	WT
45	35	III	-	-	1+	WT
46	51	II	+	-	1+	WT
47	44	III	-	-	3+	WT
48	37	III	-	-	1+	WT
49	45	II	+	+	1+	WT
50	34	III	+	+	1+	WT
51	70	I	+	+	1+	WT
52	47	II	-	-	3+	WT
53	65	I	+	+	1+	c.3140A > G: p.His1047Arg (20)
54	36	III	-	-	3+	WT
55	39	I	+	+	3+	c.1633G > A: p.Glu545Lys (9) c.3075C > T: SNP (20)
56	60	II	+	+	1+	WT
57	63	III	+	+	1+	c.1633G > A: p.Glu545Lys (9)
58	42	I	+	+	1+	WT
59	52	II	+	+	3+	c.3075C > T: SNP (20) c.3140A > G: p.His1047Arg (20)
60	49	I	+	+	1+	WT
61	60	I	+	+	1+	c.3166G > A: p.Asp1056Asn (20)
62	48	II	+	-	1+	WT
63	56	II	+	-	3+	WT
64	53	II	+	+	1+	WT
65	28	DCIS	NA	NA	1+	c.3140A > T: p.His1047Lys (20)
66	40	II	-	-	3+	c.1633G > A: p.Glu545Lys (9)
67	45	III	-	-	3+	WT
68	44	NA	NA	NA	NA	c.1633G > A: p.Glu545Lys (9)
69	45	MET	-	-	1+	c.3075C > T: SNP (20)
70	22	II	+	+	1+	WT
71	37	III	-	-	1+	WT
72	45	III	-	-	3+	c.3140A > G: p.His1047Arg (20)
73	46	II	-	-	1+	WT
74	49	III	+	+	3+	WT
75	46	III	+	-	3+	WT
76	51	III	-	-	3+	WT
77	53	I	+	-	1+	c.3140A > G: p.His1047Arg (20)
78	48	III	+	+	1+	WT
79	39	II	+	+	3+	WT
80	40	II	-	-	3+	WT
81	36	II	-	-	3+	WT

Mutations are shown as nucleotide change followed by amino acid change and the number of exon in parenthesis. Abbreviations: ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2; WT, wild type; NA, information not available; MET, metastatic; DCIS, ductal carcinoma in situ.